New in @CD_AACR! 👏
Dr. Ruth Scherz-Shouval and colleagues unravel a pathway of CAF-mediated suppression of NK cells in #BreastCancer, opening possible avenues for new biomarkers and strategies for immune-based therapies. #TumorMicroenviromment
🔗 https://t.co/23KHnBBHLW
Why do bacteria talk to each other?
Julie Valastyan (Bassler Lab, @Princeton) studies cell-cell communication to understand how bacteria behave, in hopes that scientists can one day design new therapies to combat bacterial infections. 🧫🧠
More than five years after CAR T-cell therapy, Kelly is celebrating graduations, weddings and everyday moments with her family.
It is an honor to share her story and drive progress in cell therapy in pursuit of potential cures.
Let me tell you a story about golf balls.
Not just any golf ball—but the Titleist Pro V1.
The ball you probably grew up believing was the best.
But here’s the thing: is that reputation actually earned?
Or are they just really good at marketing? 🧵
A chondrocyte cell experiencing laser optical force in fluid flow measured with Laser Force Cytology (LFC). LFC measures 2 dozen biophysical and biochemical parameters for every cell in real time. It's used for quantitative predictive cellular analytics throughout biomanufacturing of vaccines, cell, and gene therapies.
https://t.co/YYlSRVeeEK
Interesting and worrying at the same time… AI draws on existing knowledge and by definition peer review of papers is new work, so how can AI ‘judge’ appropriately?
AI is transforming peer review — and many scientists are worried
Artificial intelligence software is increasingly involved in reviewing papers, provoking interest and unease. https://t.co/DoXOJXp9E1 @Nature
A paralysed man can stand on his own after receiving an injection of neural stem cells to treat his spinal cord injury. The Japanese man was one of four individuals in a first-of-its-kind trial that used reprogrammed stem cells to treat people who are fully paralysed. https://t.co/ScnIMdVPyS @Nature
#MEDIA: The European Commission has approved our #CARTcelltherapy for patients living with relapsed or refractory follicular lymphoma (FL). Read more: https://t.co/W3TCZ938C8
Preparing for CAR T cell therapy: A roadmap for patient selection, bridging therapies, and lymphodepletion. This review highlights the critical steps to optimize outcomes for B-cell malignancies.
A must-read for oncology cell therapy! Nature Review #CARTCellTherapy #OncologyResearch
https://t.co/IzF2VxjFBj
Announcing our inaugural Keynote Speaker for ISCT 2025!
Join us on the evening of Friday, May 9th, as Dr. Fred Applebaum discusses the status of our sector and projects into its future.
#ISCT2025
Learn more at https://t.co/tfaCEiTnmr
Beyond Viability: Healthier Cells, Better Therapies.
What if cell health wasn’t just viable, but optimal? Discover how advanced technologies are reshaping cell therapy by redefining viability. Dive into the future of healthier, more robust cells: https://t.co/WHIP8jK8i4
#CellTherapy #Innovation #CellHealth #FutureOfMedicine #BiotechBreakthrough
Join the LumaCyte Team at Advanced Therapies Week next week in Dallas, Texas. Discover groundbreaking innovations and network with industry leaders at the premier event for advanced therapies. Don’t miss your chance to explore cutting-edge research, gain insights from the brightest minds, and shape the future of healthcare. Visit us at Booth 448. Schedule a meeting with LumaCyte.
https://t.co/qoVWfuFgMb
#AdvancedTherapiesWeek #HealthcareInnovation #LumaCyte #FutureOfMedicine #Biotech #MedicalResearch #CuttingEdgeScience #Dallas2025 #AdvancedTherapies
Excited to be attending ISCT in Vancouver and really enjoyed participating in the panel discussion on PAT for cell therapy this morning! Thank you @ISCTglobal!
#ISCT2024 has officially begun! We are excited to reunite our global cell and gene therapy community in Vancouver for four days jam packed with cutting edge content!
ATCC’s Guy Pilkington, Lead Scientist, Microbiology R&D, was invited to participate in 2 round table discussions at the recent World Vaccine Congress with LumaCyte, titled "Fix your viral process."
Presented brand new @LumaCyte data @BEBPA US Bioassay Conference in Long Beach, CA this past Tuesday. We showed initial data correlating Laser Force Cytology measurements of PBMC with the killing efficiency of CAR T products - a very important step to improve the efficiency of manufacturing for this important cell therapy!
As part of a recent study co-led by HMS scientists, a novel #GeneTherapy was tested, restoring the hearing of five children who were born with a form of genetic #deafness.
#GeneTherapy#CGT https://t.co/dSSp5Ek8Up
An 11-year-old born with a genetic form of hearing loss experienced restored hearing thanks to a new #GeneTherapy. This dual adeno-associated viral vector-based therapy could be a game-changer, opening up new therapeutic possibilities. https://t.co/YMFMmQCavW